GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Intrinsic Value: Projected FCF

Cardax (Cardax) Intrinsic Value: Projected FCF : $0.00 (As of May. 20, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Cardax Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-20), Cardax's Intrinsic Value: Projected FCF is $0.00. The stock price of Cardax is $0.0002. Therefore, Cardax's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Cardax's Intrinsic Value: Projected FCF or its related term are showing as below:

CDXI's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.335
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Cardax Intrinsic Value: Projected FCF Historical Data

The historical data trend for Cardax's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardax Intrinsic Value: Projected FCF Chart

Cardax Annual Data
Trend Mar12 Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only - -29.54 -38.25 -52.96 -47.43

Cardax Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.13 -51.84 -49.74 -47.43 -44.68

Competitive Comparison of Cardax's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Cardax's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardax's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardax's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Cardax's Price-to-Projected-FCF falls into.



Cardax Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Cardax's Free Cash Flow(6 year avg) = $-2.22.

Cardax's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar21)/0.8)/Shares Outstanding (Diluted Average)
=(9.5858149152102*-2.22016+-11.352/0.8)/0.794
=-44.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardax  (OTCPK:CDXI) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Cardax's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0002/-44.675116929664
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardax Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Cardax's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardax (Cardax) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822
Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.
Executives
Paulson Capital Corp 10 percent owner 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc. 10 percent owner 5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc 10 percent owner 811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204

Cardax (Cardax) Headlines

From GuruFocus

Cardax Announces Interim Results from CHASE Clinical Trial

By PRNewswire PRNewswire 09-23-2019

Cardax Reports Q1 2020 Results

By PRNewswire PRNewswire 05-16-2020

Cardax, Inc. Announces Reverse Stock Split of Common Stock

By PRNewswire PRNewswire 01-15-2020

Cardax Reports Q3 2019 Results

By PRNewswire PRNewswire 11-14-2019

Cardax Reports Q1 2019 Results

By PRNewswire PRNewswire 05-17-2019

Cardax Reports Q2 2019 Results

By PRNewswire PRNewswire 08-15-2019

Cardax to Present at NobleCon XV

By PRNewswire PRNewswire 01-25-2019